Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 8/20 | 0.35 |
| ▸ | RARG | P13631 | 8/20 | 0.35 |
| ▸ | RARA | P10276 | 6/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736412 | 0.88 | PGR (0.38) | TYMSRARBRARGRARACYP26A1 | |
| SCHEMBL6234617 | 0.84 | PGR (0.43) | TYMSRARBRARGRARAGABRA1 | |
| SCHEMBL6239982 | 0.80 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8772592 | 0.80 | CYP26A1 (0.30) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6992256 | 0.77 | ALDH1A1 (0.42) | CYP3A4KDM4EMEN1CES2APAF1 | |
| SCHEMBL7640552 | 0.76 | RARB (0.67) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8772590 | 0.76 | RARA (0.32) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL8662092 | 0.76 | PBRM1 (0.53) | CYP3A4MALT1KDM4EALDH1A1LMNA | |
| SCHEMBL8662369 | 0.76 | TDP2 (0.40) | TYMSRARBRARGCYP3A4KDM4E | |
| SCHEMBL6240700 | 0.76 | HSD17B10 (0.44) | TYMSCYP3A4KDM4EMEN1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1042313-B1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | KLEIN ELLIOTT S (US) | 2003-11-27 | — | — | US | disclosed |
| EP-0931786-B1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0853610-B1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6521624-B1 | Prevention or amelioration of toxicity or undesired side effect caused by a retinoid compound | ALLERGAN, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6469028-B1 | ARYL-SUBSTITUTED AND ARYL AND (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE, AND 5,6-DIHYDRONAPHTHALENE DERIVATIVES | ALLERGAN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6369100-B1 | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| CN-1144217-A | Retinoid-like compounds | BRISTOL MYERS SQUIBB CO (US) | 1997-03-05 | — | — | CN | disclosed |
| US-5605915-A | TREATING SKIN DISORDERS | ALLERGAN | 1997-02-25 | — | — | US | disclosed |
| US-5599967-A | SKIN DISORDERS, VISION DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-02-04 | — | — | US | disclosed |
| US-5591858-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN | 1997-01-07 | — | — | US | disclosed |
| WO-1996033716-A1 | RARβ SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY | ALLERGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5543534-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-08-06 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5514825-A | SYNTHETIC RETINOIDS | ALLERGAN, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5489584-A | ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS; TREATING SKIN DISORDER, CARDIOVASCULAR DISORDER | ALLERGAN, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | TYMS 1971/4885RARB 7/4885RARG 4/4885 |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | TYMS 1971/4885RARB 7/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.